You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Resources & Tools

  • Adapted from Bernstein DI et al. 2015. FEV: Forced expiratory volume

    The online Asthma Control Test (ACT)

    A validated patient-based tool to assess asthma control

    Developed by medical asthma experts and validated on asthma patients, the ACT is a 5-question test to evaluate how asthma is affecting your patient’s quality of life. In just minutes, you’ll have a useful score to help determine their level of asthma control and the level of treatment needed. 1

    Go to the ACT online

  • Adapted from Bernstein DI et al. 2015. FEV: Forced expiratory volume

    The GINA Guide

    Essential information in a convenient fold-out pocket card

    The 2019 GINA asthma management and prevention guide recognises the need for partnership between the patient and HCP, emphasising good communication and shared decision-making. 2

    Download the 2019 GINA guide

References

  1. The Asthma Control Test. Available at: http://www.asthmacontroltest.com/ (last accessed April 2019).
  2. 2019 GINA Report. Available at: http://ginasthma.org/ (last accessed May 2019).
  3. Relvar Ellipta SmPC, available on www.medicines.ie (Last accessed, April 2019).

RELVAR Ellipta was developed in collaboration with INNOVIVA Inc.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse events can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

© 2019 GlaxoSmithKline Group of Companies. Relvar and Ellipta are trademarks of the GSK group of companies.

 

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting beta2-agonists
- patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.